603567 HeiLongJiang ZBD Pharmaceutical
- 10.05
- -0.08-0.79%
HeiLongJiang ZBD Pharmaceutical News
China Rejects ZBD Pharmaceutical's Application For Skin Infection Drug
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.
Improved Earnings Required Before Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Shares Find Their Feet
Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Annual Report 2023 - Revised Edition Summary.
Heilongjiang ZBD Pharmaceutical Co., Ltd. 2023 Semi-Annual Report - Revised Edition Summary.
Heilongjiang ZBD Pharmaceutical Co., Ltd. Q1/2024 Revised Report
Heilongjiang ZBD Pharmaceutical Co., Ltd. Annual Report 2023 - Revised Edition.
Heilongjiang ZBD Pharmaceutical Co., Ltd. 2023 Interim Report - Revised Version.
Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Q3 2023 Revised Report
Heilongjiang ZBD Pharmaceutical Co., Ltd. Q1 2023 Revised Report
Private Equity Firms Are Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (SHSE:603567) Biggest Owners and Were Hit After Market Cap Dropped CN¥517m
ZBD Pharmaceutical Gets Nod to Market Bromhexine Hydrochloride Injection
ZBD Pharmaceutical Gets Nod to Trial Qingjianghewei Granules
Investors Three-year Losses Continue as Heilongjiang ZBD Pharmaceutical (SHSE:603567) Dips a Further 4.6% This Week, Earnings Continue to Decline
ZBD Pharma Gets China Approval for Gastric Acid Inhibiting Tablets
Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (SHSE:603567) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable
Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Looks Inexpensive But Perhaps Not Attractive Enough
Earnings Growth of 108% Over 1 Year Hasn't Been Enough to Translate Into Positive Returns for Heilongjiang ZBD Pharmaceutical (SHSE:603567) Shareholders
Analysis
Price Target
No Data
No Data